The company had previously credited generative AI for the molecule’s discovery.
Insilico Medicine used generative AI to propose a drug candidate for pulmonary fibrosis and publicly credited AI with the discovery, but when the company filed a patent, it named five humans as inventors and omitted AI entirely.
Intellectual-property law grants invention rights only to humans, regardless of how fundamental an AI is to a discovery. Insilico Medicine uses computer models to propose drugs. The case illustrates a growing challenge as AI models generate designs as easily as ChatGPT writes notes.
For builders and operators deploying AI in research, the intellectual-property environment matters: patents on AI-generated inventions depend on naming human inventors correctly. Teams should document human involvement carefully. Intellectual-property strategy becomes a critical part of AI product development.
Watch for courts and patent offices to confront what it means to invent in the age of AI. As generative models become more capable, patent law may need to adapt beyond human-centric definitions. Companies should track legal developments, especially in drug discovery, and prepare for possible changes to inventorship rules.
What matters
- Insilico Medicine filed a patent naming five humans as inventors despite using AI to propose the drug.
- AI practitioners must understand that current IP law only recognizes human inventors.
- Watch for courts and patent offices to wrestle with AI authorship as discovery tools advance.
Why it matters
Watch for courts and patent offices to wrestle with AI authorship as discovery tools advance.
This GenAI News article was prepared in original wording using reporting and materials published by MIT Technology Review AI. Source reference: https://www.technologyreview.com/2026/08/21/1142762/the-download-space-mirrors-threats-ai-designed-drugs-credit/.
Drafted by the GenAI News review pipeline.